Ruti Aga: Six Years, and a Prescription No Clinic Ever Wrote

The Athletics Integrity Unit (AIU) statement came out on Thursday, and the first thing in it was a number — six. A six-year ban, effective from 10 September, on the Ethiopian marathoner Ruti Aga. The statement was split in two parts: two years for the presence of methylprednisolone in her sample, four years for fabricating the prescription and misleading the investigation. The detail that stopped me was not the arithmetic. It was that the "doctor" who wrote the prescription was a family member with no medical registration, who said he had used "an old prescription pad from a former workplace." The clinic whose name was on that pad stated plainly that no such pad existed.

In 2026, working as medical-staff liaison for the Chicago Fire, I started keeping a spiral ledger: every treatment, every "tight hamstring," every injection, logged with a time and a clinician's initials. The reason was simple — the club's injury reports were being phoned in from memory by people who had already left the building. After that season the rule became mechanical: no scan report, no treatment log, no dated source, no line in the copy. Aga's case is that rule turned inside out. There was no shortage of paper here. There was paper, and it was false.

Ruti Aga is 32. Her name is remembered by people who track the commercial tier of the marathon, the World Marathon Majors. She won the Tokyo Marathon in 2026. My old ledger has a second place at Berlin 2026 in roughly 2:18:34 and a winning time in Tokyo 2026 of roughly 2:20:40, and I should flag at the outset that those figures come from my own records, not from the AIU statement. The statement gives no mark, no split, no field strength. What it gives is this: a half marathon in China in March, which she won, and a sample afterwards, which came back positive. Three times she has finished second at a World Marathon Major. That is her real biography, and it is the central irony of the case — an athlete whose career was built on road times had it ended by a date on a piece of paper.

The Chinese half marathon matters because everything starts there. For East African marathoners, that circuit between Majors is a separate economy — few races, large appearance fees, low risk. For a 2:18–2:20 athlete it functions like a well-paid mid-season friendly for a footballer. The problem is that the same tier has become the AIU's highest-yield testing ground. The appearance-fee economy and the testing economy are colliding in the same races. Under road-running rules the in-competition testing window opens at 23:59 the night before the race. If someone took a knee injection three or four days earlier, the residue shows up in the sample. That technical detail is the entire architecture of this case.

Now the thing almost every report got wrong before the statement was even digested. Methylprednisolone was described as a "prohibited steroid" and said to be classed as performance-enhancing by WADA. That is imprecise and misleading. Methylprednisolone is a glucocorticoid, WADA Prohibited List class S9, not an anabolic steroid (S1). Under the current List, S9 glucocorticoids are prohibited in-competition only, by injection, oral or rectal routes. A therapeutic knee injection out of competition is entirely legal. It becomes a violation only if residues are present in competition. The hinge of this case is not the drug; the hinge is route and timing. And that is why the real tragedy here is not what an athlete took — it is that she tore up the one safety net that could have held her.

Let me put the medical logic plainly. In distance runners, knee synovitis and peri-articular inflammation are routine. In high-mileage marathon training the knee is the joint that pays the load bill first. Intra-articular or peri-articular methylprednisolone is standard sports-medicine practice, not some shadowy habit. Which means that if Aga genuinely had an injection to treat her knee, she had a valid, clean, documentable defence available: the treatment record, the doctor's name and registration, the injection date, and the gap between that date and the race. Instead she produced a prescription that failed in three separate places.

First: the clinic named on the pad did not exist. Second: the person who wrote it was a family member with no medical registration. Third: that person said he had used an old prescription pad left over from a former workplace — and that workplace disowned the pad in plain words. Three independent verifications, three failures. Since 2026 I have worked on a three-source rule: club side, player side, and one independent clinical document. When two agree and the third is absent, I write that the club has not confirmed. In this case all three sources existed and all three pointed the same way — at paper with nothing behind it. The clinic had no existence; the paper did. That paper did not save her two years. It added four.

The arithmetic deserves attention because the story lives there. Two years for the presence violation. That is the figure that sits when the substance is on the Specified list and deliberate cheating is not proven — the panel accepted that the drug was in her body without accepting that it was taken to enhance performance. Four years for tampering, the Code's standard sanction, not an exceptional severity. Total six. But the arithmetic tells us something specific: the panel refused the no-significant-fault mitigation. Had that mitigation been granted, the two-year presence figure could have come down, potentially to a reprimand. It was not granted, because she used a false document to protect herself. The loop closes on itself: a forged document is circumstantial evidence of concealment intent, and that same intent removes the mitigation.

Where the tampering charge came from is the fine point. It did not come from documents alone. It came from an interview — from statements made under questioning. Language and translation conditions in AIU interviews remain a recurring point of contention, particularly with athletes whose first language is not English and whose advisers are not in the room. I am not arguing that Aga was treated unjustly here. I am arguing that the fourth year was built in that room, not in a laboratory. An athlete could have escaped in two years; she added four in her own statement.

Then the question I am asked first as a team doctor liaison: where was the TUE? If an athlete has a chronically bad knee and needs a corticosteroid injection, there are two clean paths. One — obtain or apply for a Therapeutic Use Exemption, which gives documentary legitimacy to the gap between injection date and race date. Two — observe the WADA route-specific washout so that no residue is present on competition day. Neither path appears anywhere in this file. An athlete working with a credentialed team physician has those two routes by default. An athlete who does not have them is left with what this case shows: a family "doctor," an old pad, and a story.

A team doctor liaison hears what the press release leaves out. I write that line because the AIU statement does not say whether Aga had credentialed medical staff around her. In my experience that absence is the loudest signal in the document. An athlete who has won a World Major and stood on three Major podiums, and still has no clean record of a knee injection, is evidence of a governance failure, not an individual one. Injury news travels fast; injury truth travels with paperwork. Here the news travelled in March and the truth did not arrive until autumn.

Treat the knee as the root of the case, and the root looks chronic. The March race was not a sudden accident. If a prescription had to be manufactured, the likelihood is that no durable treatment pathway existed beforehand. That is the most dangerous pattern in the marathon economy. Appearance fees are paid for racing, racing requires a knee, and a knee requires time — and time is the one item not on a March calendar. In that loop a glucocorticoid is the cheapest, most available, fastest tool. A tool for masking pain. Note also that masking knee pain does not improve performance; it worsens the knee. The substance that drew the two-year sanction is not known to build endurance. This is a doping case in which the doping delivered no benefit — except that the pain showed less.

People often ask me how Indian athletics differs from East African road running. My answer is that the risk is identical but the incentive architecture is inverted. In India the athlete often has a Railways, Services or PSU job that functions as a shield; to protect the job the athlete hides pain, takes an early camp release, and trusts the medical bulletin. In Ethiopian road running there is no such shield; there is an appearance fee, paid for racing and not for resting. Both systems produce the same output — concealed pain. The difference is the instrument. In India the instrument of concealment is often administrative, a fitness certificate. Here the instrument was pharmaceutical. In 46 years of watching this, the cases that scare me most are not the careless athletes. They are the ones with no affordable way to do the right thing.

On the competitive map the ban changes almost nothing, and that needs saying because several reports are calling it a blow to Ethiopian marathoning. Ethiopia's women's marathon depth is such that a 2:18 performer is not automatically selectable. Aga's three Major silvers were commercial-tier results, not championship conversions. Her removal does not move Ethiopia's medal capacity by any measurable margin. What does move is the enforcement map. Across recent AIU road-running cases I see a pattern: an initial substance violation, then a fabricated or altered explanation layered on top. The enforcement frontier has shifted from detection to document verification. Aga's case is the cleanest example in that family.

Career arithmetic is merciless. A six-year ban at 32 means a return at roughly 38. In Ethiopian depth, a 38-year-old with a doping record on file is effectively unselectable. The 2028 Olympic cycle is gone entirely. And the record that survives is split down the middle: the 2026 Tokyo title and three Major silvers are proof of a genuinely world-class athlete, while the ban makes her commercially radioactive in a sport where distance-running sponsorship is already thin. The March result and its prize money should be treated as annulled — that is standard AIU practice — although the statement does not spell out the disqualification scope. This is where I repeat my old habit: what is not written in the statement will not survive a hearing, and what is written still needs its date checked.

Now the counter-intuitive conclusion, without which the case is misread. The heaviest sanction here did not come from the drug. The drug drew two years, which is standard for the category. The real sentence came from the paper — four years — and those four years are what make this career-terminal. The document she built to protect herself became the cause of her career's death. Had she brought a truthful record to the investigation — a doctor's name, a date, a route, a gap between injection and race — there may have been no case at all, and if there was one, it would have sat inside the mitigation range. The second inversion is in the media language. By calling methylprednisolone a "steroid," the coverage created an atmosphere in which this looked like an anabolic doping case. In fact S9 substances are prohibited in competition only, and this one has no proven endurance benefit. The misclassification turned the story into one where the athlete looks like a cheat, when the actual story is of an injured runner with no doctor and a calendar. The paper ledger said cleared; the knee was saying something else.

The third inversion is institutional. A six-year ban on a substance with no proven endurance benefit will be cited from both directions — as proof of AIU rigour and as proof of disproportionate enforcement against African road runners. My reading is that the rigour here is real, and so is the question: if enforcement is this exacting on documents, who created the vacuum the document filled? The family member who wrote the prescription is named in the statement. The agent or manager who accepted or suggested it is not. That silence is the case's largest incompleteness, and it is the same silence that surrounded the Achilles file in 2026. The Achilles file was thin; the silence around it was not.

What comes next? An appeal route exists — to CAS, typically within about 21 days of the reasoned decision. A forged-document finding is document-based and hard to overturn. The thing to watch is not the appeal. It is whether the AIU, in the next case from the same family, sanctions only the athlete or begins investigating the entourage that supplies old prescription pads. Until that question is asked, the next injured runner on a March start line will make the same choice, because she will not have another one. Six years is not a diagnosis; it is a question with a calendar — and the calendar still belongs to the entourage.